Q-LINEA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.01 SEK | +0.50% |
|
-2.90% | -45.68% |
| Mar. 13 | Q-linea AB Presents Strong ASTar Results At AMCLI | CI |
| Feb. 27 | Transcript : Q-linea AB, Q4 2023 Earnings Call, Feb 27, 2024 |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -45.68% | 21.59M | C | ||
| -12.24% | 19.32B | A | ||
| -46.68% | 2.7B | C+ | ||
| +16.10% | 1.83B | - | - | |
| -3.24% | 1.63B | - | ||
| +20.72% | 1.2B | B+ | ||
| -21.52% | 896M | - | C- | |
| -7.73% | 726M | - | ||
| -15.33% | 701M | B+ | ||
| +13.44% | 527M | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- QLINEA Stock
- Ratings Q-linea AB
